Our Publications

1. Treatment recalcitrant cases of tinea corporis/cruris caused by T. mentagrophytes - interdigitale complex with mutations in ERG11 ERG 3, ERG4, MDR1 MFS genes & SQLE and their potential implications. Bhattacharyya A, Sadhasivam S, Sinha M, Gupta S, Saini S, Singh H, Khurana A, Sachdeva S, Sardana K, Ghosh S. Int J Dermatol. 2023 May;62(5):637-648. doi: 10.1111/ijd.16622. 
2. A potent antibiotic-loaded bone-cement implant against staphylococcal bone infections. Ghosh S, Sinha M, Samanta R, Sadhasivam S, Bhattacharyya A, Nandy A, Saini S, Tandon N, Singh H, Gupta S, Chauhan A, Aavula KK, Varghese SS, Shi P, Ghosh S, Garg MK, Saha T, Padhye A, Ghosh S, Jang HL, Sengupta S.
Nature Biomed Eng. 2022 Oct;6(10):1180-1195
3. Checkerboard Analysis To Evaluate Synergistic Combinations of Existing Antifungal Drugs and Propylene Glycol Monocaprylate in Isolates from Recalcitrant Tinea Corporis and Cruris Patients Harboring Squalene Epoxidase Gene Mutation. Sardana K, Gupta A, Sadhasivam S, Gautam RK, Khurana A, Saini S, Gupta S, Ghosh S. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0032121. doi: 10.1128/AAC.00321-21. Epub 2021 Jul 16.
4. Mechanistic Insight Into the Antifungal Effects of a Fatty Acid Derivative Against Drug-Resistant Fungal Infections. Bhattacharyya A, Sinha M, Singh H, Patel RS, Ghosh S, Sardana K, Ghosh S, Sengupta S. Front Microbiol. 2020 Sep 8;11:2116. doi: 10.3389/fmicb.2020.02116. eCollection 2020.
5. Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes. Batra R, Sadhasivam S, Saini S, Gupta S, Bisen RKS, Sinha M, Ghosh S, Jain S. Drugs R D. 2020 Jun;20(2):95-104. doi: 10.1007/s40268-020-00299-z.
6. Newly Developed Anti-Dandruff Regimen, VB-3222, Delivers Enhanced Sensorial and Effective Therapeutic Benefits Against Moderate Adherent Dandruff. Sadhasivam S, Garkhal K, Singh H, Yadav V, Chawrai S, Ramnane M, Jain S, Sardana K, Ghosh S. Clin Cosmet Investig Dermatol. 2020 Feb 21;13:187-195. doi: 10.2147/CCID.S219109. eCollection 2020.
7. A Rationally Designed Multifunctional Antibiotic for the Treatment of Drug-Resistant Acne. Ghosh S, Sinha M, Bhattacharyya A, Sadhasivam S, Megha J, Reddy S, Saini S, Singh H, Kumar D, Kaur SP, Mishra M, Usharani D, Ghosh S, Sengupta S. J Invest Dermatol. 2018 Jun;138(6):1400-1408. doi: 10.1016/j.jid.2017.11.041. 
8. Library of novel fluoroquinolones with coveted antibiotic properties to combat drug resistant skin pathogens. A. Bhattacharyya, R. Samanta, A. Nandy, H. Singh, S. Saini, S. Gupta, S. Sadhasivam, M. Sinha, M. Mishra, S. Ghosh, S. Ghosh, S. Sengupta. GRC Drug resistance, 2018, Smithfield, RI, USA
9. A rationally designed multi-functional fluoroquinolone against recalcitrant implant-associated microbial infections. S. Ghosh, S. Ghosh, R. Samanta, S. Saini, A. Nandy, S. Gupta, S. Sadhasivam, A. Bhattacharyya, M. Mishra, M. Sinha, S. Sengupta. GRC Drug resistance, 2018, Smithfield, RI, USA
10. A Novel Fluoroquinolone with Broad-spectrum Antimicrobial Activity: A Potential Therapy Against Implant-Associated Infections. S. Ghosh, S. Ghosh, R. Samanta, S. Saini, A. Nandy, S. Gupta, M. Sinha, S. Sadhasivam, A. Bhattacharyya, M. Mishra, S. Sengupta. ASM Microbe 2018, Atlanta, Georgia, USA
11. Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff. Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S. BMC Dermatol. 2017 May 3;17(1):5. doi: 10.1186/s12895-017-0058-5.
12. Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. Sadhasivam S, Sinha M, Saini S, Kaur SP, Gupta T, Sengupta S, Ghosh S, Sardana K. Dermatol Ther. 2016 Nov;29(6):451-454. doi: 10.1111/dth.12391.
13. Antibiotic-resistant acne: getting under the skin. Sinha M, Sadhasivam S, Bhattacharyya A, Jain S, Ghosh S, Arndt KA, Dover JS, Sengupta S. Semin Cutan Med Surg.2016 Jun;35(2):62-7. doi: 10.12788/j.sder.2016.031.
For more details, please write to us: contact@vyometx.com

Copyright © 2024 Vyome Therapeutics, Inc. All rights reserved.
Developed by Kenovate Solutions

Targeting immuno-inflamation and rare diseases